Oragenics, Inc.
New York Stock Exchange ArcaCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Janet Huffman
- Full Time Employees
- 3
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 9015 Town Center Parkway Lakewood Ranch FL United States of America 34202
- IPO Date
- Feb 25, 2004
- CIK
- 0001174940
- Website
- oragenics.com
- Similar Companies
- Business
- Oragenics, Inc. (NYSE American: OGEN) is a clinical-stage biotechnology company that develops brain-targeted therapeutics through proprietary intranasal delivery technology for neurological disorders; its lead product candidate, ONP-002, is a fully synthetic neurosteroid designed to treat mild traumatic brain injury and concussion by reducing swelling, oxidative stress, inflammation, and restoring blood flow via rapid blood-brain barrier penetration; the intranasal platform also supports pipeline expansion into neurodegenerative diseases, CNS disorders, Parkinson's, Alzheimer's, PTSD, and anxiety. Founded in 1996 through the merger of Access Pharmaceuticals and university-derived research, originally focused on oral health and infectious diseases including lantibiotics and legacy COVID-19 vaccine NT-CoV2-1, the company is headquartered in Sarasota, Florida, with a subsidiary in Australia to leverage R&D incentives and conducts Phase IIa clinical trials there while preparing U.S. Phase IIb trials. Recent developments include the 2024 acquisition of ONP-002 assets marking a strategic pivot to neurology, Q3 2025 strategic partnership with Receptor.AI to apply AI-driven drug discovery for optimizing prior molecule portfolios and accelerating multi-asset development, contracts with Sterling Pharma Solutions for cGMP manufacturing and Southern Star Research as CRO, regaining NYSE American compliance in October 2025 after a $16.5 million capital raise via Series H preferred stock that eliminated debt and restored equity above $6 million, securing Human Research Ethics Committee approval with amendments pending for Q4 2025 Phase IIa trial initiation, and 30% year-over-year R&D expense reduction alongside 5% lower total operating costs through September 2025.
Company News
Oragenics Reports Continued Clinical Progress, Provides Regulatory and NYSE American Listing Update
Oragenics (NYSEAMERICAN:OGEN) Trading Up 0.2% – Time to Buy?
Oragenics Achieves Full Activation of Australian Phase IIa Trial Network — All Three Sites Now Enrolling
Oragenics to Present at Sidoti's Micro-Cap Virtual Investor Conference May 20-21
ORAGENICS PROVIDES INVESTOR UPDATE
ORAGENICS PROVIDES INVESTOR UPDATE
Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation
Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation
Oragenics Activates Second Site in Phase IIa Clinical Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury.
Oragenics Reports 8 study drug doses in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury
Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury
Short Interest in Oragenics, Inc. (NYSEAMERICAN:OGEN) Rises By 39.0%
Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation
ORAGENICS INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATION
ORAGENICS EXPLORES EXPANSION OF CNS PLATFORM PURSUING ACQUISTION OF ASSETS IN BRAIN HEALTH, RECOVERY, AND NEUROPROTECTION
Oragenics Receives HREC Approval for Phase IIa Clinical Trial of ONP-002 as a Treatment for Concussion and Mild Traumatic Brain Injury in Australia
Oragenics (NYSEAMERICAN:OGEN) Trading Down 0.3% – Here’s Why
Oragenics Targets Projected $9 Billion Market by Advancing First and Only Clinical-Stage Concussion and Mild Traumatic Brain Injury Therapy
Oragenics Partners with DUCK FLATS Pharma to Support FDA IND Readiness and Clinical Trial Design for Concussion Program
Oragenics to Participate in SCOPE Summit 2026 Focused on Advancing Clinical Research and Patient Care